Loading patent…
AssigneeImmatics Biotechnologies GmbH
InventorsToni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh
Estimating the term…
The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
A peptide not more than 30 amino acids in length comprising an amino acid motif capable of binding to a human major histocompatibility complex (MHC) class-I molecule, wherein said amino acid motif is a sequence selected from the group consisting of SEQ ID NO:
An immunogenic peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:
Dependencies are inferred from the claim text.